Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 52 | UKINETS2017 | Next issue

UKI NETS 15th National Conference

Poster Presentations

(1)

Table of contents

ea0052p01 | (1)

Genetics and diagnostic characterisation of bladder paragangliomas

ea0052p02 | (1)

Validation of a blood biomarker test for the diagnosis and management of bronchopulmonary neuroendocrine tumors

ea0052p03 | (1)

Blood measurements of Neuroendocrine Tumor (NET) transcripts and gene cluster analysis predict efficacy of PRRT

ea0052p04 | (1)

A liquid biopsy for the diagnosis and monitoring of bronchopulmonary/lung carcinoid

ea0052p05 | (1)

Incidence of PCC/PGL in mutation positive family members at first contact

ea0052p06 | (1)

Nutritional assessment and vitamin deficiencies in patients with NETs

ea0052p07 | (1)

Piloting a group programme aiming at psychologically supporting neuroendocrine patients

ea0052p08 | (1)

Audit of a new nurse-led non-medical prescribing (NMP) clinic for systemic anti-cancer agents (SACTs)

ea0052p09 | (1)

Audit of South Wales Neuroendocrine MDT pathology reports

ea0052p10 | (1)

Neuroendocrine Tumour (NET) patients experiences of support in the community setting across the cancer treatment trajectory

ea0052p11 | (1)

The Missing Malignancies - Follow up of patients with pulmonary carcinoid tumours in the UK: Results from the National Lung NET Pathway (‘LEAP’) project

ea0052p12 | (1)

1-Year survival rates for neuroendocrine tumour patients in England

ea0052p13 | (1)

Metachronous primary cancers in neuroendocrine tumour patients

ea0052p14 | (1)

Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

ea0052p15 | (1)

Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice

ea0052p16 | (1)

Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: post-hoc analyses from TELESTAR

ea0052p17 | (1)

Surgical therapy for appendiceal neuroendocrine tumours: is appendicectomy adequate?

ea0052p18 | (1)

Circulating Tumour Cells (CTCs) are associated with bone metastases in patients with Neuroendocrine Tumours (NET)

ea0052p19 | (1)

Mixed Adeno-Neuroendocrine Carcinoma (MANEC): a multicentre retrospective study

ea0052p20 | (1)

Prophylactic right hemicolectomy in Appendiceal Neuroendocrine Neoplasms: challenging the current indications

ea0052p21 | (1)

Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence

ea0052p23 | (1)

Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)

ea0052p24 | (1)

Shortened interval of octreotide LAR administration for the treatment of advanced neuroendocrine tumours (NETs)

ea0052p26 | (1)

Multi-parametric assessment improves prognostication of small bowel neuroendocrine neoplasms: external validation of the NET nomogram

ea0052p27 | (1)

Supplementation of vitamin D deficiency/insufficiency in patients with GEP-NET using over the counter vitamin D3 preparations

ea0052p28 | (1)

Outcomes of radical treatment of NET Liver Metastases: a single tertiary centre 18-year experience

ea0052p29 | (1)

Endoscopic submucosal dissection (ESD) of gastric and rectal neuroendocrine tumours (NETs)

ea0052p30 | (1)

Outcomes of surgical and endoscopic resection of duodenal NETs: a systematic review of the literature

ea0052p31 | (1)

The utility of the KI67-Index in predicting pulmonary carcinoid metastasis: a single centre experience

ea0052p32 | (1)

Impact of somatostatin analogues on quality of life in patients with neuroendocrine tumours

ea0052p33 | (1)

Double-balloon enteroscopy (DBE) is useful and effective for the diagnosis, assessment and management of small bowel neuroendocrine tumours (SBNETs): a case series from a national tertiary referral centre

ea0052p34 | (1)

Grading systems in gastroenteropancreatic neuroendocrine tumours

ea0052p35 | (1)

A family of SDHB mutation and paraganglioma Alam K, Owen D, Ganatra R, Nakas A, Lloyd D, Levy MJ university hospitals of Leicester NHS trust

ea0052p36 | (1)

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

ea0052p37 | (1)

Choroidal metastases as a Harbinger of Metastatic Typical Pulmonary Carcinoid: regression and stability with Lanreotide autogel

ea0052p38 | (1)

Paraneoplastic syndrome or De Novo diagnosis?: Metastatic small bowel neuroendocrine tumour presenting with Giant cell arteritis

ea0052p39 | (1)

A case of carcinoid crisis despite high dose somatostatin analogue therapy peri-operatively

ea0052p40 | (1)

Pancreatic VIPoma – a diagnostic and symptom control challenge

ea0052p41 | (1)

Two cases of metastatic neuroendocrine tumours stabilised with somatostatin analogues

ea0052p42 | (1)

Therapeutic options in metastatic phaeochromocytomas

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more